



ASX ANNOUNCEMENT

Lumos Receives Research & Development Tax Rebate

MELBOURNE, Australia (10 Aug 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received a cash refund of A\$705,193 related to its Research and Development Tax Incentive for the FY2022 financial year ending 30 June 2022.

This cash refund primarily relates to R&D conducted by Lumos on the further development and optimisation of its proprietary reader technology platform which facilitates the reading and interpretation of results from point-of-care diagnostic tests and enables them to seamlessly interface with electronic medical record systems. This reader platform has been a highly valued element of our services offering to clients and has been instrumental in our recent contract wins with Hologic and the Burnet Diagnostics Initiative of the MacFarlane Burnet Institute for Medical Research and Public Health Ltd.

The Australian Government’s Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% or eligible expenditure on research and development activities.

“We are extremely grateful for the support provided by the Federal Government’s Research and Development Tax Incentive Scheme,” said Doug Ward, CEO and Managing Director of Lumos. “For our Company, this refund has provided a much needed source of funding which has enabled us to progress the research and development work on our reader technology platform and as well as progress our development of novel point of care tests to improve human health outcomes.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598